The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | The impact of daratumumab refractoriness on clinical outcomes following CAR-T in R/R myeloma
Bruno Costa, MD, Icahn School of Medicine at Mount Sinai, New York, NY, provides insight into a study on the outcomes of patients with daratumumab-refractory multiple myeloma (MM) treated with BCMA-directed CAR T-cell therapies, specifically ciltacabtagene autoleucel (cilta-cel), idecabtagene vicleucel (ide-cel), and orvacabtagene autoleucel (orva-cel). The retrospective analysis included 127 patients and compared response rates between daratumumab-refractory and non-refractory groups. Results showed similar outcomes for both groups despite higher disease burden in the refractory cohort, suggesting BCMA-directed CAR T-cell therapies remain effective for heavily pre-treated patients. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
